TIDMC4XD
RNS Number : 6858E
C4X Discovery Holdings PLC
09 November 2020
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS
RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH
AFRICA, NEW ZEALAND OR IN ANY OTHER STATE OR JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER
TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION,
INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC
OF SOUTH AFRICA AND NEW ZEALAND. NEITHER THIS ANNOUNCEMENT NOR
ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED
UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY
JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU.
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Result of General Meeting and Issue of Equity
Total Voting Rights
9 November 2020 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, is pleased to announce that at
the General Meeting held earlier today in connection with the
Company's Placing at an Issue Price of 14.0 pence, details of which
were announced on 21 October 2020, each of the Resolutions were
duly passed.
As a consequence and conditional on, amongst other things,
Admission, the Company has raised approximately GBP15.0 million
(before expenses and excluding any proceeds arising from the
exercise of the Warrants) in aggregate through the issue of
99,169,286 Units and 7,973,572 EIS/VCT Placing Shares.
Application has been made for the 107,142,858 Placing Shares to
be admitted to trading on AIM. It is expected that First Admission,
in respect of 7,973,572 EIS/VCT Placing Shares, will take place at
8.00 a.m. on 10 November 2020 and that Second Admission, in respect
of 99,169,286 General Placing Shares, will take place at 8.00 a.m.
on 11 November 2020. The 99,169,286 Warrants will be unlisted and
no application will be made for the Warrants to be admitted to
trading on AIM.
Total voting rights
Following Second Admission, the total issued ordinary share
capital of the Company will consist of 226,346,002 Ordinary Shares.
The Placing Shares will rank pari passu with the existing ordinary
shares of the Company. The Company does not hold any shares in
treasury. Therefore, the total number of voting rights in the
Company will be 226,346,002. The above figure of 226,346,002 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure Guidance and Transparency Rules.
The capitalised terms used in this announcement have the same
meanings as in the announcement published by the Company at
approximately 7.06 a.m. on 21 October 2020 unless otherwise
stated.
The person responsible for arranging the release of this
information is Clive Dix, CEO of the Company.
For further information, please contact:
C4X Discovery Holdings plc
Mo Noonan, Communications 0787 6444977
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)
020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Chris Gardner 0203 709 5700
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
Drug Discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m, which is now in a Phase I
clinical study.
C4XD has a state-of-the-art suite of proprietary technologies
across the Drug Discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
IMPORTANT NOTICES
This Announcement has been issued by, and is the sole
responsibility of, the Company.
The content of this Announcement has not been approved by an
authorised person within the meaning of the Financial Services and
Markets Act 2000 (as amended).
This Announcement is for information purposes only and is
directed only at: (a) persons in member states of the European
Economic Area who are qualified investors ("qualified investors")
as defined in Article (2)(e) of Regulation EU/2017/1129 (the
"Prospectus Regulation"); and (b) in the United Kingdom, qualified
investors who are persons (1) who have professional experience in
matters relating to investments falling within Article 19(1)
(Investment Professionals) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (as amended) (the
"Order"); (2) falling within Article 49(2)(a) to (d) (High net
worth companies, unincorporated associations, etc.) of the Order;
or (3) other persons to whom it may otherwise lawfully be
communicated without being accompanied by any further statements
and/or warnings required by the Order and not included in this
Announcement (all such persons together being referred to as
"Relevant Persons").
This Announcement must not be acted on or relied on by persons
who are not Relevant Persons. Any investment or investment activity
to which this Announcement or the Placing relates is available only
to Relevant Persons and will be engaged in only with Relevant
Persons. As regards all persons other than Relevant Persons, the
details of the Placing set out in this Announcement are for
information purposes only.
Panmure Gordon (UK) Limited, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority (the
"FCA"), is acting as Nominated Adviser and broker to the Company
and no one else for the purposes of the AIM Rules for Companies and
the AIM Rules for Nominated Advisers in connection with the
Placing. Accordingly, it will not be responsible to any person
other than the Company for providing the regulatory and legal
protections afforded to customers of Panmure Gordon (UK) Limited or
for advising any other person on the contents of this Announcement
or any matter, transaction or arrangement referred to in it.
This Announcement may not be published, distributed, forwarded
or transmitted directly or indirectly, in whole or in part, in or
into the United States. These materials do not constitute an offer
to sell, or a solicitation of an offer to buy, securities in the
United States.
This Announcement and the information contained herein are not
for publication or distribution in the United States or to any U.S.
person ("US Person") within the meaning of Regulation S
("Regulation S") under the United States Securities Act of 1933, as
amended (the "Securities Act"). Any failure to comply with this
restriction may constitute a violation of United States securities
laws.
The Relevant Securities (or any part thereof) described in this
Announcement have not been, and will not be, registered under the
Securities Act or under the securities laws of any state or other
jurisdiction of the United States, and may not be offered, sold,
resold, transferred or delivered, directly or indirectly, within,
in or into the United States or to any US Person, unless registered
under the Securities Act or conducted pursuant to an exemption
from, or in a transaction not subject to, the registration
requirements of the Securities Act and in compliance with any
applicable securities laws of any state or other jurisdiction of
the United States. The Relevant Securities are being offered and
sold solely outside of the United States in offshore transactions
in accordance with Regulation S to investors who are not US
Persons. There will be no public offering of the Relevant
Securities in the United States, the United Kingdom or
elsewhere.
Furthermore, the Relevant Securities (or any part thereof) have
not been and will not be registered under the applicable laws of
any of Canada, Australia, Japan, the Republic of South Africa, New
Zealand or of any other jurisdiction where to do so would be
unlawful and, consequently, may not be offered or sold to any
national, resident or citizen thereof. The distribution of this
Announcement and the Placing of the Relevant Securities as set out
in this Announcement in certain jurisdictions may be restricted by
law. No action has been taken that would permit an offering of such
shares or possession or distribution of this Announcement or any
other offering or publicity material relating to such securities in
any jurisdictions where action for that purpose is required.
Persons into whose possession this Announcement comes are required
to inform themselves about, and to observe, such restrictions. Any
failure to comply with the applicable restrictions may constitute a
violation of the securities laws of any such jurisdiction.
--S---
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMUPGPPGUPUGGB
(END) Dow Jones Newswires
November 09, 2020 06:24 ET (11:24 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024